secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032101
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt
--------------------------------------------------------------------------------

- Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.
- Net loss $85.1M ($0.60/sh) vs $66.9M ($0.50) prior year; positive cash inflow $11.8M.
- Raises FY2026 revenue guidance by $120M midpoint to $2.74B-$2.82B; gross margin expected 64%-66%.
- Operating expenses $538.6M (+36.0%) on headcount growth and clinical trial expenses.
- Cash and equivalents $1,087.9M; debt $80.3M under line of credit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000162828026032101/0001628280-26-032101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000162828026032101/ntra-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer